Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
AstraZeneca
Express Scripts
McKinsey
Moodys

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,432,294

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,432,294 protect, and when does it expire?

Patent 7,432,294 protects KALETRA and NORVIR and is included in two NDAs.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,432,294
Title:Pharmaceutical formulations
Abstract:Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
Inventor(s): Alani; Laman (Morris Plains, NJ), Ghosh; Soumojeet (Lansdale, PA)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:11/546,673
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,432,294
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 7,432,294

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 DISCN No No   Start Trial   Start Trial Y   Start Trial
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Dow
Merck
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.